# A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

> **NCT04343989** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 178 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Clazakizumab 25 mg
- **DRUG:** Clazakizumab 12.5 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04343989
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-31
- **Primary completion:** 2021-02-03
- **Final completion:** 2021-03-12
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2022-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04343989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04343989, "A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04343989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*